Global Markets Direct's, 'Hematological Tumor - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hematological Tumor, complete with latest updates, and special features on late-stage and discontinued projects. https://www.reportscorner.com/reports/23244/Hematological-Tumor-%E2%80%93-Pipeline-Review,-H1-2013/

1. RC
Reports Corner
Hematological Tumor – Pipeline Review, H1 2013
3

2. DescriptionDescription
Reports Cornerwww.reportscorner.com
Global Markets Direct's, 'Hematological Tumor - Pipeline Review,
H1 2013', provides an overview of the indication's therapeutic
pipeline. This report provides information on the therapeutic
development for Hematological Tumor, complete with latest
updates, and special features on late-stage and discontinued
projects.

3. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Global Markets Direct's, 'Hematological Tumor - Pipeline Review,
H1 2013', provides an overview of the indication's therapeutic
pipeline. This report provides information on the therapeutic
development for Hematological Tumor, complete with latest
updates, and special features on late-stage and discontinued
projects. It also reviews key players involved in the therapeutic
development for Hematological Tumor. Hematological Tumor -
Pipeline Review, Half Year is built using data and information
sourced from Global Markets Direct's proprietary databases,
Company/University websites, SEC filings, investor presentations
and featured press releases from company/university sites and
industry-specific third party sources, put together by Global
Markets Direct's team.
Note*: Certain sections in the report may be removed or altered
based on the availability and relevance of data for the indicated
disease.

4. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Scope
- A snapshot of the global therapeutic scenario for Hematological
Tumor.
- A review of the Hematological Tumor products under
development by companies and universities/research institutes
based on information derived from company and industry-specific
sources.
- Coverage of products based on various stages of development
ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and
combined therapeutics.
- Coverage of the Hematological Tumor pipeline on the basis of
route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

5. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Reasons to buy
- Identify and understand important and diverse types of
therapeutics under development for Hematological Tumor.
- Identify emerging players with potentially strong product
portfolio and design effective counter-strategies to gain
competitive advantage.
- Plan mergers and acquisitions effectively by identifying players
of the most promising pipeline.
- Devise corrective measures for pipeline projects by
understanding Hematological Tumor pipeline depth and focus of
Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope.

6. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
- Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from
pipeline.

7. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Table of Contents
Table of Contents 2
Introduction 5
Hematological Tumor Overview 6
Therapeutics Development 7
Hematological Tumor Therapeutics under Development by Companies 9
Hematological Tumor Therapeutics under Investigation by Universities/Institutes 14
Mid Clinical Stage Products 15
Early Clinical Stage Products 16
Discovery and Pre-Clinical Stage Products 17
Hematological Tumor Therapeutics – Products under Development by Companies 18
Hematological Tumor Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Hematological Tumor Therapeutics Development 25
Hematological Tumor – Therapeutics Assessment 83
Drug Profiles 88

8. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Hematological Tumor Therapeutics – Drug Profile Updates 206
Hematological Tumor Therapeutics – Discontinued Products 244
Hematological Tumor Therapeutics - Dormant Products 245
Hematological Tumor – Product Development Milestones 248
Appendix 254

9. For more informationFor more information
Reports Cornerwww.reportscorner.com
For more information please visit our website
https://www.reportscorner.com/reports/23244/Hematological-Tumor-%E2%80%93-
Pipeline-Review,-H1-2013/

10. Reports Corner
Thank YouThank You
www.reportscorner.com
RC
Contact us: contact@reportscorner.com